New hope for kids with rare kidney disease: drug trial launches

NCT ID NCT07024563

First seen Jan 06, 2026 · Last updated May 01, 2026 · Updated 13 times

Summary

This study tests a drug called ravulizumab in children aged 2 to 18 with a kidney disease called IgA nephropathy. The goal is to see how the drug works in the body, if it is safe, and if it can reduce protein in the urine, a sign of kidney damage. About 24 children will take part, and they must already be on a stable dose of standard blood pressure medication.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMMUNOGLOBULIN A NEPHROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Research Site

    NOT_YET_RECRUITING

    Palo Alto, California, 94304, United States

  • Research Site

    RECRUITING

    Aurora, Colorado, 80045, United States

  • Research Site

    RECRUITING

    Beijing, 100045, China

  • Research Site

    RECRUITING

    Shanghai, 201102, China

  • Research Site

    RECRUITING

    Genova, 16147, Italy

  • Research Site

    RECRUITING

    Roma, 00165, Italy

  • Research Site

    RECRUITING

    Torino, 10126, Italy

  • Research Site

    RECRUITING

    Wakayama, 641-8510, Japan

  • Research Site

    RECRUITING

    Seoul, 03080, South Korea

  • Research Site

    RECRUITING

    Barcelona, 08035, Spain

  • Research Site

    RECRUITING

    Barcelona, 8950, Spain

  • Research Site

    RECRUITING

    Seville, 41013, Spain

  • Research Site

    RECRUITING

    Taipei, 10002, Taiwan

  • Research Site

    RECRUITING

    Taoyuan District, 333, Taiwan

Conditions

Explore the condition pages connected to this study.